BioNexus Gene Lab Corp. Business Combination, Consideration Transferred
BioNexus Gene Lab Corp. (BGLC) reported Business Combination, Consideration Transferred of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-06.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2022-04-06
- BioNexus Gene Lab Corp. business combination, consideration transferred for the quarter ending 2021-12-31 was $0.00.
- BioNexus Gene Lab Corp. business combination, consideration transferred for the quarter ending 2021-09-30 was $0.00.
- BioNexus Gene Lab Corp. business combination, consideration transferred for the quarter ending 2021-06-30 was $0.00.
- BioNexus Gene Lab Corp. business combination, consideration transferred for the quarter ending 2021-03-31 was $0.00.
- BioNexus Gene Lab Corp. business combination, consideration transferred for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- BioNexus Gene Lab Corp. business combination, consideration transferred for fiscal 2020 was $147.88K.
- BioNexus Gene Lab Corp. business combination, consideration transferred for fiscal 2019 was $0.00.
| Period end | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 9 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-06 | $0.00 derived: sum of 2 quarters · filed 2022-04-06 | $0.00 derived: sum of 3 quarters · filed 2022-04-06 | $0.00 10-K · filed 2022-04-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-18 | |||
| 2020-12-31 | $147.88K 10-K · filed 2022-04-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |